UK cost-effectiveness agency NICE has backed Novartis’ Mayzent for secondary progressive multiple sclerosis (SPMS), after turning it down earlier this year in draft guidance.
Eli Lilly is to buy the private biotech Disarm Therapeutics, which is working on a new class of disease-modifying drugs for neurological diseases, in a deal worth up to $1.36 billion.
A north-south divide threatens to emerge in multiple myeloma in the UK, after the Scottish Medicines Consortium (SMC) backed NHS use of two drugs previously turned down by NICE in England.<
Patients with the rare disease familial chylomicronemia syndrome (FCS) will be able to access treatment with Akcea’s Waylivra via the NHS, after a U-turn by NICE.
UK cost-effectiveness watchdog NICE has changed its stance on AstraZeneca’s Tagrisso as a first-line therapy for non-small cell lung cancer (NSCLC) after an improved “commercial arrangement